Open Access

Effect of HCV treatment response on insulin resistance: A systematic review and meta‑analysis

  • Authors:
    • Jing‑Hong Hu
    • Ming‑Ling Chang
    • Nai‑Jen Liu
    • Chu‑Ting Yeh
    • Tung‑Jung Huang
  • View Affiliations

  • Published online on: September 11, 2019     https://doi.org/10.3892/etm.2019.7995
  • Pages: 3568-3578
  • Copyright: © Hu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Sustained virological response (SVR) in hepatitis C virus (HCV) patients treated with pegylated interferon α‑2a and ribavirin is associated with reduced insulin resistance (IR), measured as a reduction of homeostasis model assessment (HOMA) scores after 24 weeks of therapy, and reduced fasting serum insulin and serum glucose levels. The present meta‑analysis aimed to evaluate the effect of HCV treatment response on IR in HCV patients who achieved SVR and those who did not (non‑SVR) after receiving interferon (IFN)‑based therapy. The PubMed, Cochrane and Embase databases were searched using combinations of the following search terms: ‘HCV’, ‘hepatitis C’, ‘interferon’, ‘antiviral’, ‘treatment response’ and ‘insulin resistance’. The incidence of IR, HOMA‑IR and HOMA‑β, as well as fasting glucose and fasting insulin levels, were summarized in terms of basal values and values after the end of treatment for each study. A total of 8 studies were included in the final analysis. There was no significant difference in the reduction in IR between the SVR and non‑SVR groups (odds ratio, 0.995; 95% CI=0.613‑1.616; P=0.984). However, the SVR group had a significantly higher mean reduction in HOMA‑IR (difference in means=‑0.485; 95%CI=‑0.713 to ‑0.256; P<0.001) and HOMA‑β (difference in means=‑15.448; 95%CI=‑23.326 to ‑7.570; P<0.001) compared to the non‑SVR group. In conclusion, HCV patients who achieved SVR after IFN‑based therapy exhibited improvement in HOMA‑IR and HOMA‑β. The present results suggest that clinical management of IR and serum glucose levels may be an important way to impact the therapeutic response in HCV patients.
View Figures
View References

Related Articles

Journal Cover

November 2019
Volume 18 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Hu, J., Chang, M., Liu, N., Yeh, C., & Huang, T. (2019). Effect of HCV treatment response on insulin resistance: A systematic review and meta‑analysis. Experimental and Therapeutic Medicine, 18, 3568-3578. https://doi.org/10.3892/etm.2019.7995
MLA
Hu, J., Chang, M., Liu, N., Yeh, C., Huang, T."Effect of HCV treatment response on insulin resistance: A systematic review and meta‑analysis". Experimental and Therapeutic Medicine 18.5 (2019): 3568-3578.
Chicago
Hu, J., Chang, M., Liu, N., Yeh, C., Huang, T."Effect of HCV treatment response on insulin resistance: A systematic review and meta‑analysis". Experimental and Therapeutic Medicine 18, no. 5 (2019): 3568-3578. https://doi.org/10.3892/etm.2019.7995